Hydrolysis spectrum extension of CMY-2-like β-lactamases resulting from structural alteration in the Y-X-N loop

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1151-1156

  Dahyot, Sandrine ^a   Mammeri, Hedi ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFALORIDINE; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CMY 2 BETA LACTAMASE; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CATALYSIS; CITROBACTER FREUNDII; ENZYME PURIFICATION; ESCHERICHIA COLI; HYDROLYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MOTIF; SITE DIRECTED MUTAGENESIS;

ADULT; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CITROBACTER FREUNDII; CLONING, MOLECULAR; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; HUMANS; HYDROLYSIS; KINETICS; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PERITONITIS; POSTOPERATIVE COMPLICATIONS; PROTEIN STRUCTURE, TERTIARY;

EID: 84857184513     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05630-11     Document Type: Article

References (44)

1. Ahmed AM, Shimamoto T. 2008. Emergence of a cefepime- and cefpirome-resistant Citrobacter freundii clinical isolate harbouring a novel chromosomally encoded AmpC β-lactamase, CMY-37. Int. J. Antimicrob. Agents 32:256 -261.
2. Barnaud G, et al. 2004. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob. Agents Chemother. 48:1040-1042. (Pubitemid 38280365)
3. Barnaud G, et al. 2001. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol. Lett. 195:185-190. (Pubitemid 32155376)
4. Bauernfeind A, Chong Y, Schweighart S. 1989. Extended broad spectrum β-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection 17:316-321. (Pubitemid 19254313)
5. Bellais S, Aubert D, Naas T, Nordmann P. 2000. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing β-lactamases in Chryseobacterium meningosepticum. Antimicrob. Agents Chemother. 44:1878-1886. (Pubitemid 30422942)
6. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement. M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Cornish-Bowden A. 1995. Fundamentals of enzyme kinetics, p 30-37. Portland Press, Seattle, WA.
8. Crichlow GV, et al. 1999. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 38:10256-10261.
9. Doi Y, et al. 2009. Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase. Antimicrob. Agents Chemother. 53:3159-3161.
10. Doi Y, et al. 2004. Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob. Agents Chemother. 48:2652-2658. (Pubitemid 38823438)
11. Dubus A, Normark S, Kania M, Page MGP. 1994. The role of tyrosine 150 in catalysis of β-lactam hydrolysis by AmpC β-lactamase from Escherichia coli investigated by site-directed mutagenesis. Biochemistry 33: 8577-8586. (Pubitemid 24242697)
12. Guillon H, Tande D, Mammeri H. 2011. Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum β-lactamase AmpC. Antimicrob. Agents Chemother. 55:4443- 4446.
13. Hancock RE, Bellido F. 1992. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J. Antimicrob. Chemother. 29(Suppl A):1-6.
14. Hidri N, et al. 2005. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamase of a Serratia marcescens clinical isolate. J. Antimicrob. Chemother. 55:496-499. (Pubitemid 40542589)
15. Jacob F, Joris B, Lepage S, Dusart J, Frère J-M. 1990. Role of the conserved amino acids of the 'SDN= loop (Ser130, Asp131 and Asn132) in a class A β-lactamase studied by site-directed mutagenesis. Biochem. J. 271:399-406. (Pubitemid 20344753)
16. Jacobs C, et al. 1995. AmpD, essential for both β-lactamase regulation and cell wall recycling, is a novel cytosolic N-acetylmuramyl-L- alanine amidase. Mol. Microbiol. 15:553-559.
17. Joris B, et al. 1988. The active-site-serine penicillin-recognizing enzymes as members of the Streptomyces R61 DD-peptidase family. Biochem. J. 250:313-324.
18. Kim JY, et al. 2006. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol. Microbiol. 60: 907-916.
19. Laemmli UK, Favre M. 1973. Maturation of the head of bacteriophage T4. I. DNA packaging events. J. Mol. Biol. 80:575-599.
20. Lee SH, Jeong SH, Park YM. 2003. Characterization of blaCMY-10 a novel, plasmid-encoded AmpC-type β-lactamase gene in a clinical isolate of Enterobacter aerogenes. J. Appl. Microbiol. 95:744-752. (Pubitemid 37186657)
21. Lindquist S, Galleni M, Lindberg F, Normark S. 1989. Signalling proteins in enterobacterial AmpC β-lactamase regulation. Mol. Microbiol. 3:1091-1102.
22. Lobkovsky E, et al. 1993. Evolution of an enzyme activity: crystallographic structure at 2-Å resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc. Natl. Acad. Sci. U. S. A. 90:11257-11261. (Pubitemid 23354408)
23. Mammeri H, Eb F, Berkani A, Nordmann P. 2008. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. J. Antimicrob. Chemother. 61:498-503. (Pubitemid 351321120)
24. Mammeri H, Galleni M, Nordmann P. 2009. Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC β-lactamases in Escherichia coli. Antimicrob. Agents Chemother. 53:323-326.
25. Mammeri H, Guillon H, Eb F, Nordmann P. 2010. Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases. Antimicrob. Agents Chemother. 54: 4556-4560.
26. Mammeri H, et al. 2004. AmpC β-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins. Antimicrob. Agents Chemother. 48:4050-4053. (Pubitemid 39304647)
27. Mammeri H, Nordmann P, Berkani A, Eb F. 2008. Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol. Lett. 282:238-240. (Pubitemid 351569457)
28. Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. 2004. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob. Agents Chemother. 48:716-720. (Pubitemid 38280315)
29. Mammeri H, Poirel L, Fortineau N, Nordmann P. 2006. Naturally occurring extended-spectrum cephalosporinases in Escherichia coli. Antimicrob. Agents Chemother. 50:2573-2576. (Pubitemid 43993209)
30. Mammeri H, Poirel L, Nordmann P. 2007. Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J. Antimicrob. Chemother. 60:490-494. (Pubitemid 47299861)
31. Matsumura N, Minami S, Mitsuhashi S. 1998. Sequences of homologous β-lactamases from clinical isolates of Serratia marcescens with different substrate specificities. Antimicrob. Agents Chemother. 42:176-179. (Pubitemid 28053348)
32. Nordmann P, Mammeri H. 2007. Extended-spectrum cephalosporinases: structure, detection, and epidemiology. Future Microbiol. 2:297-307. (Pubitemid 47180926)
33. Nukaga M, et al. 1995. Molecular evolution of class C β-lactamase extending its substrate specificity. J. Biol. Chem. 270:5729-5735.
34. Nukaga M, Kumar S, Nukaga K, Pratt RF, Knox JR. 2004. Hydrolysis of third-generation cephalosporins by class C β-lactamases. Structures of a transition state analog of cefotaxime in wild-type and extended spectrum enzymes. J. Biol. Chem. 279:9344-9352. (Pubitemid 38295999)
35. Nukaga M, Tsukamoto K, Yamaguchi H, Sawai T. 1994. Interaction of oxyimino β-lactams with a class C β-lactamase and a mutant with a spectrum extended to β-lactams. Antimicrob. Agents Chemother. 38:1374-1377. (Pubitemid 24170722)
36. Oefner C, et al. 1990. Refined crystal structure of β-lactamase from Citrobacter freundii indicates a mechanism for β-lactam hydrolysis. Nature 343:284-288.
37. Pettersen EF, et al. 2004. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
38. Philippon A, Arlet G, Jacoby GA. 2002. Plasmid-determined AmpC type β-lactamases. Antimicrob. Agents Chemother. 46:1-11.
39. Powers RA, Caselli E, Focia PJ, Prati F, Shoichet BK. 2001. Structures of ceftazidime and its transition-state analogue in complex with AmpC β-lactamase: implications for resistance mutations and inhibitor design. Biochemistry 40:9207-9214. (Pubitemid 32730042)
40. Raimondi A, Sisto F, Nikaido H. 2001. Mutation in Serratia marcescens AmpC β-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob. Agents Chemother. 45:2331-2339. (Pubitemid 32664475)
41. Reisbig MD, Hanson ND. 2004. Promoter sequences necessary for highlevel expression of the plasmid-associated ampC β-lactamase gene blaMIR-1. Antimicrob. Agents Chemother. 48:4177- 4182.
42. Rodríguez-Martínez J-M, Nordmann P, Ronco E, Poirel L. 2010. Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:3484-3488.
43. Rodríguez-Martínez J-M, Poirel L, Nordmann P. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4783-4788.
44. Vakulenko SB, et al. 2002. Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob. Agents Chemother. 46:1966-1970. (Pubitemid 34535222)